Relmada Therapeutics will host a conference call on November 13 to discuss third-quarter financial results and business updates.
Quiver AI Summary
Relmada Therapeutics, Inc. has announced a conference call and webcast scheduled for November 13, 2025, at 4:30 PM ET to discuss its financial results for the third quarter of 2025 and recent business developments. The call can be accessed via specific dial-in numbers for both US and international participants, with a webcast link provided. After the event, a replay will be available on the Investors section of Relmada's website. Relmada is a clinical-stage biotechnology company focused on innovative therapies for oncology and central nervous system disorders, with its lead candidates, NDV-01 and sepranolone, currently in mid-stage clinical development.
Potential Positives
- Relmada Therapeutics is advancing innovative therapies for oncology and central nervous system indications, highlighting its commitment to addressing significant medical needs.
- The company is hosting a conference call to discuss its third-quarter financial results and recent business progress, indicating transparency and engagement with investors.
- Relmada's lead candidates, NDV-01 and sepranolone, are progressing through mid-stage clinical development, suggesting potential advancements in their product pipeline.
Potential Negatives
- The press release does not contain any information about positive developments or milestones related to the company's drug candidates, which may lead to concerns about progress and investor confidence.
- There is no mention of financial performance details, which could raise questions about the company's current financial health and stability.
FAQ
When will Relmada Therapeutics host its conference call?
Relmada Therapeutics will host its conference call on Thursday, November 13, 2025, at 4:30 PM ET.
How can I access the Relmada Therapeutics conference call?
You can access the conference call by dialing 1-877-407-0792 for US participants or 1-201-689-8263 for international participants.
Will there be a replay available for the conference call?
Yes, a replay of the webcast will be available in the Investors section of the Relmada website after the event.
What recent business progress will be discussed in the conference call?
The conference call will discuss financial results for Q3 2025 and recent business progress by Relmada Therapeutics.
Where can I find more information about Relmada Therapeutics?
More information about Relmada Therapeutics can be found on their official website at www.relmada.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RLMD Insider Trading Activity
$RLMD insiders have traded $RLMD stock on the open market 15 times in the past 6 months. Of those trades, 15 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $RLMD stock by insiders over the last 6 months:
- MAGED SHENOUDA (Chief Financial Officer) has made 4 purchases buying 700,000 shares for an estimated $1,197,208 and 0 sales.
- SERGIO TRAVERSA (Chief Executive Officer) has made 7 purchases buying 888,476 shares for an estimated $952,307 and 0 sales.
- CHUCK ENCE (CAO and COO) has made 2 purchases buying 364,961 shares for an estimated $402,530 and 0 sales.
- PAUL EDWARD KELLY (Chief Operating Officer) has made 2 purchases buying 290,000 shares for an estimated $284,060 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RLMD Hedge Fund Activity
We have seen 19 institutional investors add shares of $RLMD stock to their portfolio, and 20 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC removed 843,998 shares (-69.9%) from their portfolio in Q2 2025, for an estimated $506,651
- DRIEHAUS CAPITAL MANAGEMENT LLC added 740,006 shares (+inf%) to their portfolio in Q2 2025, for an estimated $444,225
- ACADIAN ASSET MANAGEMENT LLC removed 608,449 shares (-49.6%) from their portfolio in Q2 2025, for an estimated $365,251
- PALO ALTO INVESTORS LP removed 495,146 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $297,236
- TWO SIGMA ADVISERS, LP removed 262,900 shares (-91.3%) from their portfolio in Q2 2025, for an estimated $157,818
- CORIENT PRIVATE WEALTH LLC added 206,667 shares (+inf%) to their portfolio in Q2 2025, for an estimated $124,062
- MARSHALL WACE, LLP added 154,568 shares (+inf%) to their portfolio in Q2 2025, for an estimated $92,787
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2025 and recent business progress.
Conference Call and Webcast Information:
- Date: Thursday, November 13, 2025 at 4:30 PM ET
- Participant Dial-in (US): 1-877-407-0792
- Participant Dial-in (International): 1-201-689-8263
- Webcast Access: Click Here
A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar .
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.
For more information, visit www.relmada.com
Investor Contact:
Brian Ritchie
LifeSci Advisors
[email protected]
Media Inquiries:
Corporate Communications
[email protected]
